ptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements after the date of this release.
Unigene Laboratories, Inc.
VP, Investor Relations and Business Administration
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
Page: 1 2 3 4 5 6 7 8 9 10 11 Related medicine technology :1
|SOURCE Unigene Laboratories, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 92
. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist3
. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.4
. Unigene Reports Third Quarter 2011 Financial Results5
. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 20116
. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call7
. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch8
. VIVUS Provides Qnexa Regulatory Update9
. New Product Planning Excellence Services Program Provides Road Map for Clinical Development Success in the Pharmaceutical Industry10
. ViroPharma Provides 2012 Outlook11
. Cogmedix Provides High-Precision Subassembly for LensAR Revolutionary Refractive Laser